Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners
Eurofins GeLaMed to provide test kit processing of ColoAlert® through Germany. BERKELEY, US – MAINZ, Germany – [May 3, 2023] — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has added Eurofins GeLaMed to its network of lab partners […]
Mainz Biomed to Participate in Digestive Disease Week 2023
Largest international meeting of physicians, researchers, and academics covering gastroenterology, hepatology, endoscopy, and gastrointestinal surgery BERKELEY, US – MAINZ, Germany – May 1, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its participation in the annual Digestive Disease […]
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
BERKELEY, US – MAINZ, Germany – April 27, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the following activities in May: Commencement of Voluntary Quarterly Reporting: Under the disclosure requirements of the U.S. NASDAQ listing, foreign issuers are required to […]
Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
The Instituto de Microecologia to market at-home detection test for colorectal cancer to physicians and their patients. BERKELEY, US – MAINZ, Germany – [April 26, 2023] — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has added the Instituto de […]
Mainz Biomed Provides Full Year 2022 Financial Results
ColoAlert Revenue Increases 130% Year over Year Year End Cash Balance of $17.1 Million BERKELEY, US – MAINZ, Germany – April 10, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the fiscal year ended […]
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
BERKELEY, US – MAINZ, Germany – [April 4, 2023] — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that three German-based companies, have selected ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer (CRC) into their respective corporate […]
Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas
Mainz Biomed’s proprietary nucleic acid extraction and PCR process proved to be highly effective Two mRNA biomarkers found to be particularly valuable in detecting disease signals in advanced adenoma samples eAArly DETECT clinical trial evaluating these biomarkers with fresh samples reporting results mid-year 2023 Results of eAArly DETECT will inform possible inclusion in U.S. Pivotal […]
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
BERKELEY, US – MAINZ, Germany – March 21, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced that Bill Caragol, the Company’s CFO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on […]
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
Labor Staber to actively market and sell ColoAlert to its physician and patient network. BERKELEY, US – MAINZ, Germany – [March 15, 2023] — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber & Kollegen GmbH (Labor […]
Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
Sponsor of Gastro Update 2023, 2-day scientific and training events for gastroenterology professionals Patient Education Day in the City of Mainz, Germany, where the Company is headquartered Germany-based molecular diagnostic specialist to support local colorectal cancer communities BERKELEY, US – MAINZ, Germany – March 8, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), […]
